Toripalimab
Metastatic Malignant Neoplasm In The Colon
Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
China Medical University, China
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07277322CT.gov Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06283134CT.gov A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06547203CT.gov Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study | — | Recruiting | — | — | — |
NCT06283303CT.gov A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT06525428CT.gov Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05963490CT.gov Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT03927898CT.gov Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | China Medical University, China | P2 | B · 56 |
| Binimetinib | Pierre Fabre Medicament | P3 | BB |
| Irinotecan | Oncolytics Biotech | P4 | BB |
| Aflibercept | Sanofi | P3 | BB |
| Adriamycin | Northwell Health | P4 | B |
| Durvalumab | University of Iowa | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Centre Georges Francois Leclerc | P2 | B |
| Famitinib | Jiangsu HengRui Medicine Co., Ltd. | P3 | B |
| Vemurafenib | Fudan University | P3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Colon cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-metastatic-malignant-neoplasm-in-the-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →